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screened for associated abnormalities. Autoimmune, non-genetic
hypoparathyroidism is still a diagnosis of exclusion, since no spe-
cific autoantibodies are specific for this condition.
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The term hypoparathyroidism encompasses a broad series of disorders of mineral metabolism of
different etiologies, all characterized by inadequate or insufficient parathyroid hormone (PTH) secre-
tion leading to hypocalcemia, hyperphosphatemia and related signs and symptoms [1e4].
PTH is the main regulator of calcium homeostasis and, together with fibroblast growth factor 23
(FGF23), of phosphate homeostasis. The most important consequences of the missing or abnormal
parathyroid function can be ascribed to the lack of direct or indirect PTH actions on main organs
devoted to the maintenance of calcium homeostasis such as the kidneys, bone and intestine. These
organs express the PTH 1 receptor (PTH1R), a G-protein coupled receptor transducing PTH and PTH
related peptide (PTHrP) effects on target cells [5]. The interaction of PTH on PTH1R on renal proximal
tubular cells enhances the hydroxylation of 25 hydroxyvitamin D [25(OH)D], thus producing 1,25
dihydroxy vitamin D [1,25(OH)2D], i.e. calcitriol, the biologically active hormone responsible of active
calcium and phosphate absorption from the intestinal lumen. Parathyroid function is mainly regulated
by extracellular calcium ions ([Ca2þ]), which interact with the calcium sensing receptor (CaSR), another
G-protein coupled receptor primarily expressed on the parathyroid cell membrane and on renal
tubular cells [6]. CaSR is a key regulator of calcium homeostasis. When [Ca2þ] transiently increases the
receptor is activated and transcription of PTH gene, translation into mature protein and secretion are
inhibited [6]. The relationship between secreted PTH and extracellular calcium ([Ca2þ]), expressed by a
sigmoidal curve, is maintained although shifted towards left or right even in the case of PTH insuffi-
ciency or excess, respectively, thanks to the expression of at least one copy of the CaSR gene [6]. At the
renal tubular level, CaSR is involved in regulating calcium reabsorption.
In the case of PTH inadequacy, intestinal calcium and phosphate absorption decrease. At the kidney
level, the tubular transport of calcium (TmCa) is decreased and the tubular transport of phosphate
(TmP) is increased, so that individuals with hypoparathyroidism are also prone to hypercalciuria and
hyperphosphatemia in addition to the main feature, i.e. hypocalcemia [7]. Hypocalcemia is the main
responsible for the development of signs and symptoms related to muscular hyperexcitability, while
long-standing hyperphosphatemia leads to the occurrence of soft tissue calcifications (i.e. basal ganglia
calcifications, subcapsular cataract). The tendency towards hypercalciuria, which gets worse under
calcium and active vitamin D replacement therapy, increase the risk of nephrolithiasis, in particular
under calcium and calcitriol replacement therapy. Besides the cohort of sign and symptoms directly
related to the disturbances in mineral homeostasis, signs and symptoms due to the lack of PTH action
on various tissues and organs such as bone expressing the PTH1R may be present [1].
The products of key developmental genes drive the patterning and migration of the parathyroids,
which arise from the third and fourth pharyngeal pouches endoderm with neural crest contribution
[8]. Since these developmental structures give rise to multiple organs other than the parathyroids,
alterations in these genes are responsible of complex syndromes, in which hypoparathyroidism is
usually associated with other clinical manifestations [9]. Conversely, mutations in genes encoding for
proteins active at later stages of parathyroid development will give rise to isolated hypoparathyroidism
[9]. Syndromic or isolated hypoparathyroidism are usually also referred to as genetic or congenital
hypoparathyroidism, despite the fact that they can manifest only in adult life.
Removal, anatomic or vascular damage to the parathyroids during neck surgery (mainly thyroid-
ectomy or parathyroidectomy) represents the main cause of acquired hypoparathyroidism, i.e. post-
surgical hypoparathyroidism [10]. Immune-mediated damage of the parathyroids is another cause of
acquired hypoparathyroidism, and is usually associated with other autoimmune disorders [11].
Divalent ions, such as magnesium [Mg2þ], are important both in PTH secretion and action and in
muscle excitability. Hypomagnesemia can blunt PTH secretion, may cause peripheral end-organ
resistance to PTH and increase neuromuscular excitability per se, so causing a functional, reversible
hypoparathyroidism or exacerbating a pre-existing hypoparathyroidism related symptoms [12]. Hy-
poparathyroidism as a consequence of infiltrative diseases or external beam radiation is a very rare
event.
Within the different causes, acquired hypoparathyroidism is the most frequent form, and, within
this, postsurgical hypoparathyroidism is the most frequent one, followed by autoimmune hypopara-
thyroidism [9]. It is estimated that the proportion between postsurgical forms versus non-surgical
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of non-surgical forms. This is due first of all to the increased expertise in endocrine neck surgery and
the increased number of endocrine surgery referral centers leading to diminished risk of causing
surgical hypoparathyroidism. In addition, because of the improved clinical expertise in diagnosing
non-surgical forms of hypoparathyroidism, the increased knowledge of parathyroid development,
differentiation and function with the possibility to apply specific genetic tests, the number of identi-
fication and proper diagnosis of non surgery-related hypoparathyroidism, once defined as idiopathic,
has gradually increased. Still, proper genetic diagnostic procedures related to non-surgical hypo-
parathyroidism are like to be carried out in endocrine referral centers.
Epidemiology of hypoparathyroidism
Data on the prevalence and incidence of hypoparathyroidism as a whole and of the different sub-
types are still scarce in a number of settings. Epidemiological data on the disease have been carried out
mainly in countries where non-anonymous disease registries are available, such as USA and Denmark
[14e16]. Recently, in Italy epidemiological studies have been carried out analyzing anonymous health
registries through ICD codes, hospital discharge codes and prescription of chronic therapy with active
vitamin D [17,18]. No such reports are still available in Asia, South America, Africa, Australia.
Overall, hypoparathyroidism is overall considered a rare disease (i.e. affecting fewer than 1 in
1000e200,000, according to various international definitions), in particular as long as the genetically
determined, congenital conditions are considered. Nonetheless, available epidemiological reports
reflect mainly the epidemiology of postsurgical hypoparathyroidism, since still the majority of adult
cases represent a consequence of neck surgery. In children non-surgical, genetic causes are more
common [19].
In the USA, the prevalence of hypoparathyroidism, as estimated by the analysis of a large insurance
claims database over a one-year period, was 77,000 cases in a population of approximately 300 million
individuals (i.e. 25 cases/100,000 adults-year) [14]. Analogous figures emerged from a smaller longi-
tudinal study performed in Rochester, Minnesota (USA), in which the prevalence of chronic hypo-
parathyroidismwas 37 cases/100,000. Similar studies carried out in Denmark, where non-anonymous
regional and national health registries are available, has shown a comparable overall prevalence of
hypoparathyroidism of 25.4 cases/100,000 individuals [15]. The prevalence in other European coun-
tries such as Norway or Italy, as calculated by the analysis of hospital discharge ICD codes, has appeared
to be lower (i.e. 5e10 cases/100,000) [17,21]. This may be due to themethodology bywhich diagnosis of
hypoparathyroidism are retrieved. Indeed, examining just hospital-based registries can be too
restrictive and harbor a possible selection bias [20]. Recently, the indirect assessment of cases of hy-
poparathyroidism through the analysis of prescription databases belonging to an Italian region, with
detection of subjects on chronic (at least 6 month-long) therapy with active vitamin Dmetabolites, has
demonstrated a prevalence of 27 cases/100,000 [18], which is in line with previous results in other
countries.
The estimate of cases with hypoparathyroidism and their characteristics is essential in order to
select cases refractory to conventional therapy with calcium and active vitamin D suitable for therapy
with the full-length PTH, which has become available in USA and Europe.
Causes and classification of hypoparathyroidism
The various forms of hypoparathyroidism can be classified in different ways, i.e. congenital (i.e.
manifest at birth) or acquired (i.e. manifest later in life), genetic (if a specific gene alteration is iden-
tified) or non-genetic, isolated or syndromic (i.e. associated with non-parathyroid related dys-
morphisms/disturbances) disease, on the basis of clinical features and etiology (Fig. 1). A specific form
of hypoparathyroidism, i.e. autoimmune hypoparathyroidism, usually classified as acquired, can be
isolated or syndromic if associated with other (usually autoimmune) disorders, genetic or non-genetic,
depending on the presence or absence of specific mutation, as detailed later in this paper [4,9]. Genetic
hypoparathyroidism is usually referred also to as congenital hypoparathyroidism, even if the clinical
































Fig. 1. Classification of hypoparathyroid disorders according to different modalities. Hypoparathyroidism (HYPO) can be classified
according to the time of onset (congenital or acquired), presence or absence of a genetic cause (genetic and non genetic), association
with other non-parathyroid related clinical manifestations (isolated or syndromic). Acquired hypoparathyroidism is mainly non-
genetic and can be isolated or syndromic such as in non-monogenic autoimmune polyendocrinopathies. Genetic hypoparathy-
roidism, isolated or syndromic, can be congenital or inappropriately defined as acquired* in the case is not manifest at birth or
neonatally but later in life. Surgical hypoparathyroidism is an acquired form of hypoparathyroidism. Using this latter way to classify,
all the other forms of hypoarpathyroidism can be defined as non surgical.
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some genetic/hereditary forms of hypoparathyroidism with reduced penetrance and expressivity in
terms of clinical manifestations may be inappropriately defined as acquired (Fig. 1). Considering that
most cases of hypoparathyroidism ensue after neck surgery, hypoparathyroidism can be also classified
as post-surgical and non-surgical, with the latter one broadly including all the forms of different origin
(once inappropriately named as idiopathic).Genetic hypoparathyroidism
Genetic or monogenic hypoparathyroidism may ensue from developmental defects usually
involving multiple organs mainly arising from the third and fourth pharyngeal pouches, abnormalities
in genes encoding for key proteins specific for parathyroid development and function, mutations in
genes active early in life in modulating tolerance mechanisms important for adaptive immunity and
causing non-surgical damage to the parathyroids later in life, mitochondrial disorders and other rare
causes (Table 1) [4,9]. These disorders can originate from de novo or inherited mutations or chromo-
somal rearrangements, occurring in germ cells (de novo or inherited germline mutations) or at early
stages of zygote development (post-zygotic somatic mutations), determining genetic mosaicism in the
adult organism. In general, as previously stated, mutations occurring early in development will cause
broader defects involving multiple organs (syndromic hypoparathyroidism), while more specific
Table 1
Classification of genetic hypoparathyroidism according to the origin of the defect: genetically-determined abnormality in
development of multiple organs, genetically-determined abnormalities in genes encoding for key proteins for parathyroid
development and function, immune system abnormalities, mitochondrial diseases, and other disorders). If a specific gene
mutations (indicated in italic; “del.” ¼ chromosomal deletion) is responsible for the disease, it is shown in the right column (see




 DiGeorge syndrome type 1 (DGS1) del. 22q11.2 (TBX1)
 DiGeorge syndrome type 2 (DGS2) del. 10p14-p13 (NEBL)
 CHARGE syndrome CHD7
 Hypoparathyroidism, sensorineural deafness and renal dysplasia (HDR) GATA3
 Hypoparathyroidism, retardation, and dysmorphism syndrome (HRD) TBCE
 Kenny-Caffey syndrome type 1 (KCS1) TBCE
 Kenny-Caffey syndrome type 2 (KCS2) FAM111A
 Gracile bone dysplasia (GCLEB) FAM111A
Parathyroid-specific functional and developmental abnormalities
 Autosomal dominant hypocalcemia with hypercalciuria type 1 (ADH1)/Bartter syndrome
type 5
CaSR
 Autosomal dominant hypocalcemia with hypercalciuria type 2 (ADH2) GNA11
 Familial isolated hypoparathyroidism (autosomal, X-linked) (FIH) PTH, GCMB, SOX3
Immune system abnormalities
 Autoimmune polyendocrine syndrome type 1 (APS1) AIRE
 Autoimmune polyendocrine syndrome type 3 (APS3) —
 Autoimmune polyendocrine syndrome type 4 (APS4) —
Mitochondrial diseases
 Kearns-Sayre syndrome (KSS) Mitochondrial DNA
 Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes
syndrome (MELAS)
Mitochondrial DNA
 Mitochondrial trifunctional protein deficiency syndrome HADHA, HADHB
 Medium chain acylCOA dehydrogenase deficiency) ACADM
Other forms:
 Smith-Lemli-Opitz syndrome (SLOS) DHCR7
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isolated hypoparathyroidism.
Penetrance and expressivity are variable, even within subjects with a same mutation belonging to
the same kindred. This high variability may be derives from interactions with environmental and
genetic factors, which remain to be identified. Once established, the disease lasts life-long. Thus, even
in the presence of mild hypocalcemia, ectopic calcifications are likely to occur. Dental abnormalities
and bone dysplasia can be observed in the case of developmental disorders.
Genetic isolated hypoparathyroidism
Genetic isolated hypoparathyroidism encompasses a group of disorders, in which hypocalcemia
ensuing from parathyroid insufficiency is the only biochemical and functional abnormality caused by a
de novo or inherited mutation transmitted following an autosomal dominant, recessive or X-linked
pattern of inheritance. Nonetheless, the majority of the cases of genetic hypoparathyroidism are
sporadic. Isolated hypoparathyroidism may present with a wide range of disease severity, going from
life-threatening, early onset, neonatal hypocalcemia to mostly asymptomatic disease [4,9]. They are
usually manifest at birth or in the first decade of life as long as abnormalities in the PTH genes or in
genes encoding for parathyroid-specific transcription factors are responsible for the disease (overall
indicated with OMIM phenotype number #146200). In this case the disorder is very rare (less than 1
case in 1,000,000 individuals). When a functional abnormality of the parathyroids due to an altered
CaSR signaling is the cause, the disease has a higher prevalence (1:70,000 cases), usually milder clinical
manifestations, so that it might manifest in adult life or remain undiagnosed [22].
Mutations in the transcription factor GCMB (encoded by GCM2, OMIM gene number *603716,
chromosomal locus 6p24.2), one of the human hortologs of the Drosophila glial cell missing (gcm), can
L. Cianferotti et al. / Best Practice & Research Clinical Endocrinology & Metabolism 32 (2018) 909e925914be responsible of both of autosomal recessive or autosomal dominant familial isolated hypoparathy-
roidism. GCMB is a transcription factor mainly expressed in the developing and mature parathyroids
and recognized as critical for parathyroid development, differentiation and function, as demonstrated
in mice lacking Gcm2 [23]. It has been recently demonstrated also to regulate CaSR and PTH expression
in mature parathyroid cells [24]. A homozygous intragenic deletion in GMC2was first demonstrated in
the proband belonging to large kindred with familial isolated hypoparathyroidism [25]. Another loss of
function homozygous mutation in GCM2 was later shown in two siblings from asymptomatic, first
cousin parents, in whom a residual PTH secretion could be demonstrated [26]. Further studies in
families with autosomal recessive isolated hypoparathyroidism has characterised additional GCM2
mutations and shown that they can impair nuclear localization, DNA-binding or transactivational
ability of this j key parathyroid transcription factor [27]. Autosomal dominant hypoparathyroidism can
be caused by heterozygous, dominant-negative mutations in GMC2, which lead to the production of an
aberrant GCMB protein usually impairing the transactivation capacity of the wild-type protein [28,29].
A study in Indian families affected from autosomal recessive hypoparathyroidism has demonstrated
GCM2 mutations in up to 80% of the cases, even in the absence of consanguineity, maybe because of a
founder effect [27].
Mutations in the preproPTH gene (OMIM gene number *168450, chromosomal locus 11p15.2) have
described to be associated both to autosomal dominant and autosomal recessive hypoparathyroidism.
A missense mutation in the sequence of the pre-proPTH gene encoding for the hydrophobic core of the
signal peptide was first described as responsible of autosomal dominant familial isolated hypopara-
thyroidism [30]. This mutant protein is not properly processed through the endoplasmic reticulum.
Thus, it accumulates within the cytoplasm, becomes toxic and promotes apoptosis of the parathyroid
cell [31]. A homozygous mutation in the preproPTH gene described in kindreds with autosomal
recessive hypoparathyroidism has been shown to lead to aberrant preproPTH mRNA devoid of exon 2,
which contains the sequence for the signal peptide and initiation codon for protein translation [32,33].
Other homozygous mutations in exon 2 of the preproPTH gene similarly lead to aberrant or truncated
PTH propeptides impairing intracellular PTH trafficking andmaturationwithin the parathyroid cell and
are transmitted as an autosomal recessive trait, indicating exon 2 as a probable hot spot for mutations
in the preproPTH gene [34].
Some forms of early-onset, severe hypoparathyroidism due to parathyroid agenesis can be trans-
mitted as a X-linked recessive disease, thus occurring in only in males. It is a very rare condition and it
has been described just in two kindreds from the United States [35]. Chromosomal rearrangements
involving chromosomes 2p25 and Xq27 likely affect the expression of SOX3, a SRY (sex-determining
gene on chromosome Y) related high-mobility group has been demonstrated. This gene is expressed
early in developing parathyroids and is likely to regulate their growth and differentiation [36].
Recently, a compound heterozygous mutation in the autoimmune regulator gene (AIRE, OMIM gene
number *607358, chromosomal locus 21q22.3), a gene responsible for autoimmune endocrinopathy
type 1 (APS1, see paragraph 2.1.2) has recently been demonstrated to be also the cause of autosomal
recessive isolated hypoparathyroidism [37].
Mild variants of isolated hypoparathyroidism are likely to be caused by partial inactivation of CaSR
signaling [22]. Gain-of-function mutations of CaSR (OMIM number *601199 on chromosome 3q21)
cause the disorder named as autosomal dominant hypocalcemia with hypercalciuria (ADH1 or
HYPOC1, OMIM phenotype number #601198), also referred to as familial hypercalciuric hypocalcemia
[38,39]. De novo or familial heterozygous mutations in the CaSR gene may lead to a partially consti-
tutive active CaSR, which inhibits PTH transcription and secretion (PTH levels are usually in the low-
normal range), thus inducing congenital mild hypocalcemia. At the same time, fractional calcium
excretion is increased, leading to with a tendency towards or frankly overt hypercalciuria [40]. This is
the reason why the individuals with this disorder are likely to develop nephrolithiasis, renal and soft
tissue ectopic calcifications. Hypocalcemic symptoms are generally mild or absent, with few episodes
related to muscle hyperexcitability. Serum levels of magnesium are typically in the low-normal range
and may worsen the clinical manifestations. The phenotype of a Bartter-like syndrome with hypoka-
lemic alkalosis, hyperreninemic hyperaldosteronism (Bartter syndrome type 5) can accompany the
mineral disturbances in the case of specific gain-of-function mutations of CaSR [22].
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OMIM gene number *139313 on chromosome 19p13) cause ADH2 or HYPOC2 (OMIM phenotype
number #615361) [41,42]. Gaq/11 is a membrane-associated protein mediating CaSR signal trans-
duction intracellularly. The phenotype of ADH2 resembles that of ADH1, withmild, often asymptomatic
hypocalcemia, but it is usually associated with a milder degree of hypercalciuria and a overall milder
renal phenotype. Sometimes, individuals with ADH2 can present a skeletal phenotype characterized by
short stature, pointing to a possible role of Gaq/11 in development and/or postnatal growth [43].
Since the majority of patients with ADH are asymptomatic or display mild symptoms, they do not
typically require conventional treatment with calcium salt and active vitamin D metabolites, which is
indeed indicated in the case of symptomatic hypocalcemia [22]. Nonetheless, the dosage regimens has
to be carefully monitored and maintained to the minimum dose effective in controlling symptoms for
the likelihood of worsening hypercalciuria with polyuria and polydipsia, inducing nephrolithiasis, and
nephrocalcinosis/renal failure in the long-term. Thiazide diuretics may be employed in order to
decrease calciuria. CaSR antagonists (i.e. calcilytics), allosteric modulators of the CaSR, have been
indicated as the therapy of choice of ADH, for their effect of increasing serum calcium and at the same
time limiting urinary calcium excretion [44].
Genetic syndromic hypoparathyroidism
Hypoparathyroidism may occur within complex syndromes and thus appear in association with
other clinical manifestations not related to parathyroid-driven mineral disturbances. The majority of
these syndromes derive from developmental abnormalities, which may also involve organs arising
from the third and fourth pharyngeal pouches [9]. In some cases hypoparathyroidism can be associated
to skeletal dysplasia or cranial malformations, other malformations, or autoimmune diseases such
within monogenic autoimmune disorders such as APS1. Rarely, hypoparathyroidism can represent one
of the features belonging to the complex clinical picture belonging to mitochondrial diseases [9].
DiGeorge syndrome type 1 and 2 (DGS1 and 2, OMIM phenotype number #188400 and #601362,
respectively) are complex conditions determined by chromosomal abnormalities, i.e. a hemizygous
microdeletions in chromosome 22q11.2 or 10p13-14 (OMIM locus number *602054 and *601362,
respectively), ensuing de novo or inherited as an autosomal dominant trait [45,46]. Recently, in a severe
case of DGS with progressive renal failure, a double deletion in 22q11.2 and 10p13-14 has been
detected. Each of these chromosomal abnormalities determines developmental abnormalities in the
formation in the derivatives of the third and fourth pharyngeal pouches. The deleted region in DGS1
contains TBX1, whose transcript, T-box 1, is crucial for the development of thymus and the parathyroids
and its haploinsufficiency could be responsible for the DGS phenotype [47]. Indeed, in some cases of
DGS negative for chromosomal deletions, loss-of-functionmutations in TBX1 have been reported. TBX1
transcript appears to enhance GCMB expression, as demonstrated in mice TBX1 knockout in which
GCMB is downregulated. The chromosomal locus for DGS2 contains NEBL, encoding nebulette, whose
role in parathyroid development has to be clarified. A great phenotypic variability is characteristic of
DGS, which has a prevalence of 1:2000e4000 in the general population and represents the most
common microdeletion disease in humans [45]. Since specific circulating microRNAs signature has
been described in DGS, it has been hypothesized that circulating microRNAs pattern could be
responsible for DGS phenotype variability [48]. Chromosomal deletions in 22q11.2 are responsible for
90% of cases of DGS (i.e. DGS1). DGS1 is also referred to as “CATCH 22”, being characterized by cardiac
and craniofacial abnormalities, T-cell deficit due to thymic hypoplasia, cleft palate, hypocalcemia due to
hypoparathyroidism) [45]. Immunological abnormalities including both T-lymphocyte and B-lym-
phocytes deficiency, anatomic abnormalities of the heart and great vessels, and typical facies with
mouth, nose and eye defects, along with usually mild cognitive impairment and increased risk of
neurologic diseases such as autism and schizophrenia can be part of the clinical picture [49]. DGS is the
most common cause of palatal abnormalities and the second most common cause of congenital heart
diseases and developmental delay. A variable degree of penetrance and severity characterizes DGS-
related hypoparathyroidism, according to the degree of parathyroid diagnosis, without any
genotype-to-phenotype correlation. On one side of the clinical spectrum there is severe hypocalcemia
due to parathyroid agenesis, which may be present at birth. At the other side of the spectrum there is
mild hypocalcemia due to parathyroid hypoplasia, which can manifest in adulthood [45,50]. The
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[51]. Given the relative high frequency and the simple cytogenetic screening, DGS has to be always
excluded in the screening for idiopathic hypoparathyroidism, even in apparently isolated forms. In
some cases, patients diagnosed with DGS can display features belonging to CHARGE syndrome (OMIM
phenotype number #214800) [52]. In this disorder, eye and hear abnormalities, genitourinary and
heart disturbances, growth retardation can constitute typical additional features. It is due to hetero-
zygous mutations in chromodomain helicase DNA-binding 7 (CHD7, OMIM gene number *608892) or
in semaphorin 3-E gene (SEMA3E, OMIM gene number *608166), whose pharyngeal ectoderm specific
transcripts have key function in the development of pharyngeal-derived organs [53].
Syndromic hypoparathyroidism can be generated by alterations of various transcription factors
encoding proteins, whose activity is located upstream GCMB, PTH or CaSR [9].
The gene GATA3 (OMIM gene number *131320, chromosomal locus 10p14) is a zinc finger tran-
scription factor expressed early in developing kidneys, inner ear, central nervous system, thymus,
hematopoietic cell lineages and parathyroids [8]. In the parathyroid cells it regulates the expression of
GCMB and PTH [54]. Heterozygous loss-of-function mutations or dominant-negative in this gene,
which can be inherited in an autosomal dominant fashion, generate the hypoparathyroidism, deafness
and renal dysplasia syndrome (HDR, OMIM phenotype number #146255), also referred to as Barakat
syndrome or nephrosis, nerve deafness and hypoparathyroidism syndrome [55]. This syndrome is
characterized by the occurrence of mild-to-severe hypoparathyroidism (according to the degree of
parathyroid aplasia-hypoplasia), together with moderate-to-severe dysplastic renal alterations, bilat-
eral symmetrical sensorineural deafness. Other features such as neurological symptoms, anatomic
abnormalities of the genital tract and intestine, craniofacial malformations can be associated to the
classical triad. More than 90% of GATA3 mutations are clustered within the sequence encoding the N-
terminal zinc finger (ZnF1), whose function is to increase DNA binding affinity [56]. No genotype-to-
phenotype correlation exists, since the same GATA3 mutation can originate various clinical combina-
tions of hypoparathyroidism, deafness and renal dysplasia, with different grades of severity, in
particular as far as renal abnormalities are concerned [57]. Indeed, while hypoparathyroidism and
deafness have a penetrance greater than 90%, renal dysplasia has a penetrance less than 80%. In any
case, so far, GATA3 mutations seem to be responsible of cases of isolated hypoparathyroidism.
Syndromic hypoparathyroidism may occur in association with signs of skeletal dysplasia or
dysmorphism.
Both hypoparathyroidism, retardation and dysmorphism syndrome (HRDS, OMIM phenotype
number #241410, also referred to as Sanjad-Sakati syndrome) and Kenny-Caffey syndrome type 1
(KCS1, OMIM phenotype number #244460) are due to homozygous mutations in tubulin-specific
chaperone E (TBCE, OMIM gene number *604934), a molecular chaperone potentially implicated in
parathyroid gland migration and bone development [58]. In both the disorders, inherited as autosomal
recessive trait, affected individuals display a proportionate short stature (dwarfism) associated with
hypoparathyroidism and ocular abnormalities (papilledema, retinal vascular tortuosity, corneal
opacity, recurrent infections). In KCS1 bones appear overall small and thin, although cortices of the long
bones are thick at X-ray imaging with medullary stenosis. Vertebrae and pelvic bones are typically
spared. Macrocephaly due to osteosclerosis of the skull, with forehead prominence, and defective
dentition (short roots, hypo-oligodontia or microdontia) are associated features. In HRDS, described in
kindreds from the Middle East, signs of osteosclerosis are usually missing, while a typical facial dys-
morphism (deep-set eyes, abnormal external ears, frontal bossing) is present. In HRDS pituitary hor-
mone deficiencies may be associated [59].
A very sever phenotype similar to KCS1, with high perinatal lethality, is gracile bone dysplasia
(GCLEB, OMIM phenotype number #602361) [60]. These newborns display thin long bones, with
stenosis of medullary cavity, and pronounced osteocraniostenosis (OCS), with triangular face with
frontal bossing and microphtalmia. Signs of hypoparathyroidism may appear in few infants surviving
the newborn period. This disorder is caused by a heterozygous deletion (Ser342del) in the gene
encoding family with sequence similarity 111 member A (FAM111A, OMIM gene number *605292),
whose product has a role in DNA replication and chromatin maturation [60]. Heterozygous missense
mutations in FAM111A (Arg569His) have been described as the cause of Kenny-Caffey syndrome type 2
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inherited in an autosomal dominant fashion [61].
Hypoparathyroidism, as well as other endocrinopathies (i.e. hypogonadism, growth hormone
deficiency, diabetes mellitus) can be sometimes a feature of the complex phenotype of mitochondrial
diseases such as mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes
(MELAS, OMIM phenotype number #540000) and Kearns-Sayre syndrome (KSS, OMIM phenotype
number #530000), due to mutations, deletions or duplications in mitochondrial DNA (mtDNA) [62].
Other mitochondrial disorders potentially featuring hypoparathyroidism are the medium chain acyl-
CoA dehydrogenase deficiency (ACADMD, OMIM phenotype number #201450), caused bymutations of
medium chain acylCoA dehydrogenase gene (ACADM, OMIM gene number *607008 on chromosome
1p31.1) and mitochondrial trifunctional protein deficiency (MTPD, OMIM phenotype number
#609015), caused by homozygous or compound heterozygous mutations in the genes encoding the a-
subunit or the b-subunit of the mitochondrial trifunctional protein (HADHA and HADHB, OMIM gene
numbers *600890 and *143450, respectively, on chromosome 2p23.3) [62]. This protein is responsible
for the b-oxidation of fatty acids [63].
In all these mitochondrial diseases, the early-onset clinical picture is mainly related to the specific,
usually severe manifestations, although hypoparathyroidism and the other possible endocrinopaties
have to be ruled out in individuals with who survive into childhood and later stages [62].
Recently, hypoparathyroidism due to parathyroid hypoplasia has been described in some in-
dividuals with Smith-Lemli-Opitz syndrome (SLOS, OMIM phenotype number #270400), a metabolic
disorder characterized by reduced cholesterol biosynthesis and typical congenital malformations
(microcephaly with short nose, altered development of male genitalia, renal dysplasia, syndactyly), and
mental retardation. This disorder is caused by homozygous mutations in the DHCR7 gene (OMIM gene
number *602858 on chromosome 11q13.4) leading to reduced cholesterol biosynthesis [64].
Genetically-determined, syndromic hypoparathyroidism can be part of a polyendocrine syndrome,
namely autoimmune polyendocrine syndrome type 1 (APS1, OMIM phenotype number #240300), also
named as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). APS1 is a
monogenic disorder caused by inactivating mutations of the autoimmune regulator gene (AIRE, OMIM
gene number *607358 on chromosome 21q22.3) [65]. APS1 prevalence can be higher in genetically
isolated populations such as Finnish, Iranian Jewish, and Sardinians because of a founder effect. AIRE is
expressed early in the thymus and has a key role in promoting initial immunological tolerance to self-
antigens [66]. APS1 is inherited as an autosomal recessive trait, although even dominant-negative
mutations, inherited following an autosomal dominant pattern of inheritance, have been described
as responsible of the syndrome. The triad of candidiasis, hypoparathyroidism, and Addison's disease,
usually occurring in this order, characterizes APS1 [65]. Mucocutaneal candidiasis caused by T-cell
immunodeficiency, hypoparathyroidism and adrenal insufficiency usually occur at early stages, first
and second-third decades of life, respectively. Additional autoimmune endocrine and non-endocrine
autoimmune disorders (i.e. insulin dependent diabetes mellitus, autoimmune thyroid diseases,
gonadal failure, pernicious anemia, celiac disease, vitiligo, alopecia) can be associated manifestations.
Ectodermal dystrophies represented by dental abnormalities may occur [65]. Chronic inflammatory
autoreactive T-cell infiltrate can be demonstrated in affected organs as well as organ-specific auto-
antibodies. Indeed, the positivity of 21-hydroxylase antibodies strongly indicates a high probability of
developing adrenal insufficiency. Antibodies against T-helper type 17 cell-related cytokines and against
type I interferons (IFN-a and IFN-u) have been indicated as specific feature and a marker of APS1,
although not causative, likely directly correlated to the susceptibility to Candida infections and possible
protection against autoimmune-induced organ damage [67]. Conversely, autoantibodies against the
extracellular domain of the calcium sensing receptor (CaSRAbs) and against parathyroid autoantigens
such as NACTH leucine-rich-repeat protein 5 (NALP5Abs) have been demonstrated only in some cases
of APS1-related hypoparathyroidism, so that they cannot be considered amarker of the disease [68,69].
Overall, a wide spectrum of APS1 phenotypic variability exists, without any verifiable genotype-to-
phenotype correlation. Previously, the diagnosis of APS1 was made on the presence of two compo-
nents of the triad and, within affected kindred, the presence of at least one major endocrine abnor-
mality. Since hypoparathyroidism has a high penetrance (100% in females and 60% in men), according
to a recent consensus, the occurrence of hypoparathyroidism together with another manifestation of
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APS1 [70].
Non-genetic hypoparathyroidism
Non-genetic hypoparathyroidism include the most common forms of hypoparathyroidism in clin-
ical practice, such as hypoparathyroidism occurring after neck surgery and non-genetic autoimmune
hypoparathyroidism. In the case of non-genetic hypoparathyroidism, and in particular surgical hypo-
parathyroidism, clinical history can easily drive the diagnosis. Since no specific marker exists in non-
genetic autoimmune hypoparathyroidism, the diagnosis of this disorder is a diagnosis of exclusion,
or indirectly made through the concurrent presence of other autoimmune diseases.
Non-genetically determined autoimmune hypoparathyroidism
Non-genetic, autoimmune hypoparathyroidism may manifest as an isolated disorder or, more
frequently, in combination with other autoimmune conditions as it occurs in autoimmune poly-
endocrinopathy syndromes (APSs) such as APS type 3, when associated with autoimmune thyroid
diseases, or APS4, when occurring in combination with other non-thyroid autoimmune diseases [11].
Autoantibodies against parathyroid autoantigens (NALP5Abs and CaSRAbs) have been described as
associated to autoimmune hypoparathyroidism, but their specificity and sensitivity for diagnosis of
autoimmune hypoparathyroidism is low. In addition, it is not clear whether they can be simply
considered an epiphenomenon or marker of the disease or whether they have a real pathogenetic role
[11,71]. For this reason they are not assessed routinely in clinical practice. On the other hand, the
assessment of other organ-specific autoantibodies in the presence of established idiopathic hypo-
parathyroidism should be advised to indirectly suggest a possible autoimmune pathogenesis of the
disorder.
Although no definitive conclusion can be derived on the prevalence of the disease for the absence of
specific markers, it is today estimated that autoimmune hypoparathyroidism is overall the most
prevalent form of idiopathic hypoparathyroidism.
Post surgical hypoparathyroidism
Hypoparathyroidism ensuing as a complication of neck surgery and thyroid surgery, in particular, is
the most usual form of hypoparathyroidism. The parathyroids lay in close proximity to the thyroid and
share with it the same blood supply. The parathyroids can be devascularized, damaged thermically by
the bovie, or unintentionally removed during thyroid surgery or large neck dissections for infiltrative
diseases [10]. Hypoparathyroidism is the obvious consequence of subtotal parathyroidectomy for
parathyroid hyperplasia, while it occurs rarely after partial removal of the parathyroids for the high
functional reserve of these glands [72,73]. Hypoparathyroidism is defined as transient when lasting
less than 6months/usually few weeks) after surgery. Chronic or permanent hypoparathyroidism refers
to an insufficient PTH secretion persisting for more than 6 months after the surgical procedure [10].
The incidence of hypoparathyroidism after surgery strongly depends upon the extent of the
intervention and the experience of the neck surgeon. Usually, the probability of hypoparathyroidism
increases after total, subtotal or near total thyroidectomy performed in the case of thyroid cancer,
lymph node or radical neck dissections for other neck malignancies, or benign thyroid diseases such as
large multinodular goiters and Graves' disease. Conversely, partial thyroidectomy is infrequently
associated with hypoparathyroidism [10,72,73].
The experience of an endocrine surgeon is another major determinant of the incidence of surgical
hypoparathyroidism. An endocrine surgeon is considered “experienced” when he/she has performed
more than 100 thyroidectomies [10,72,73]. In tertiary referral centers for endocrine surgery the rate of
transient and permanent surgical hypoparathyroidism is typically low (5.4e9.6% and 0.5e1.7%,
respectively) [74]. In epidemiological studies performed by retrieving data from large proprietary in-
surance databases, the estimated incidence of hypoparathyroidism after neck surgery was 1.9% [14].
This rate was similar to the one obtained European Mediterranean countries such as Italy through the
indirect estimate of cases of hypoparathyroidism as the ones on chronic treatment with active vitamin
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habitants [15]. In children undergoing neck surgery, the incidence of hypoparathyroidism after neck
surgery can be as high as 7.3%, even if the operation has been performed in endocrine surgery referral
centers [75].
A number of studies have attempted to identify possible predictive factors of postoperative hypo-
parathyroidism [76]. Preoperative serum calcium and 25 hydroxyvitamin D levels, low intraoperative
PTH, have been documented as independent risk factors for transient postsurgical hypoparathyroid-
ism. As far as postoperative indexes are concerned, the determination of serum calcium and/or PTH
levels in the first day after surgery has been suggested as predictive of hypoparathyroidism [77,78].
However, hypocalcemia may also occur or worsen some days after surgery. Therefore, it is important to
obtain a measurement of albumin-corrected serum calcium levels even on the 3rde4th day after the
surgical procedure. Regarding the surgical procedure itself, the failure to identify at least 2 parathyroid
glands during neck surgery has been independently associated with the risk of developing subsequent
permanent parathyroid insufficiency [10,72,73].
Diagnostic assessment in hypoparathyroidism
Different diagnostic issues have to be considered in the various forms of hypoparathyroidism. The
diagnosis of previously defined idiopathic forms is still a challenge, but the precise classification with
the genetic cause guides the diagnostic workup. At the same time, the assessment for possible asso-
ciated non parathyroid-related disturbances helps in refining the diagnosis and at the same time in
better defining the clinical picture [9]. For instance, in cases such as ADH, the analysis of CaSR or GNA11
is of key importance to better plan the long-term treatment and avoid complications related to con-
ventional therapy.
Surgical hypoparathyroidism does not usually pose big issues regarding the diagnosis, but it re-
quires an accurate definition of the type (transient vs permanent), even in apparent established cases
[Marcocci 2012].
Functional hypoparathyroidism (i.e. magnesium disturbances) has always to be excluded in all the
possible forms of hypoparathyroidism. Indeed, besides representing a possible cause of hypopara-
thyroidism by itself, it can also worsen hypoparathyroid-related symptoms [12].Diagnostic framework in non-surgical hypoparathyroidism
In Fig. 2, a diagnostic workup of non-surgical hypoparathyroidism is proposed. The clinical picture
drives the genetic hypothesis. The complete clinical assessment looking for possible association of
organ involvement other than the parathyroids is fundamental for the diagnosis of isolated or syn-
dromic hypoparathyroidism. Themeasurement of corrected serum calcium or ionized calcium levels in
first-degree relatives of a patient with idiopathic hypoparathyroidism is necessary to exclude or
confirm familial forms [9]. Despite the increasing knowledge in this area, the diagnosis of these forms
remains difficult particularly when patients are not referred to centers of expertise, where specific
genetic diagnostic workup protocols are carried out.
Given the high frequency of DiGeorge syndrome in the general population, cytogenetic analysis to
screen for possible microdeletions on chromosomes 22 or 10 are always recommended and represent
an easy test to perform in clinical practice, even in the case of adults with apparently isolated hypo-
parathyroidism, in whom overt anatomical abnormalities or immunodeficiencies are not detected
[Palmer 2018]. In cases of childhood-onset hypoparathyroidism sequence of the major genes involved
in the pathogenesis of hypoparathyroidism can unveil a mutation in one of the genes CaSR/GNA11,
GCMB, and GATA3 in up to 35% of patients. Sequence analysis of AIRE can be useful also in cases of
isolated hypoparathyroidism or, even more so, when the APS1-related triad is recognized. In severe,
early-onset cases, the sequence of PTH gene can be undertaken. If signs of skeletal dysplasia are
recognizable, the analysis of TBCE, FAM111A, is advisable.
Genetic testing in non-surgical hypoparathyroidism is important to confirm the clinical diagnosis,
to implement the appropriate treatment, to identify family members carriers for a specific mutation.
Cytogenetic and 
genetic analyses:
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Fig. 2. Proposed flow chart for the diagnosis of non-surgical forms of hypoparathyroidism. The majority of non-surgical forms refer
to genetic hypoparathyroidism (see text for further specifications).
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The diagnosis of surgical hypoparathyroidism poses the important issues for the proper detection of
hypoparathyroidism itself and of the possible transient forms, which do not require life-long therapy
with calcium and active vitamin D metabolites.
In Fig. 3 a diagnostic workup for postsurgical hypocalcemia, and, in particular, for postsurgical
hypoparathyroidism, is proposed. Patients undergoing neck surgery have always to be checked for
serum calcium and the possible presence of hypocalcemic signs or symptoms have to be ruled out. In
the case of hypocalcemia occurring within few days after neck surgery, low serum phosphate levels
and/or high PTH indicate a PTH-independent cause of hypocalcemia. In this case, a postoperative
hungry bone syndrome, due to the rapid normalization of a high bone turnover state reverted to
normal by surgical therapy with consequent fast bone mineral accrual (i.e. hyperthyroidism, hyper-
parathyroidism), is likely. This state spontaneously resolves within few months after surgery and it is
temporary by definition. High serum phosphate and inappropriately low or undetectable PTH levels
indicate surgical hypoparathyroidism, with the need to start appropriate treatment with calcium salts
and active vitamin D [10]. Even in patients under long-term replacement therapy, transient forms of
hypoparathyroidism have to be ruled out, especially in cases in which PTH is in the low-normal range,
calcemia is in the upper normal range with normal phosphatemia. Indeed, low or untraceable PTH
levels under chronic treatment with 1 a-hydroxylated vitamin D metabolites do not exclude transient
hypoparathyroidism, since these drugs may suppress the possible residual PTH secretion. In the case
normocalcemia is maintained under down titration till the discontinuation of the replacement therapy,
permanent/chronic hypoparathyroidism can be excluded in order to avoid unnecessary long-term
therapy [7,10].
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Fig. 3. Proposed diagnostic framework in post-surgical hypoparathyroidism (see text for further specifications); * calcium salts and
active vitamin D metabolites.
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Pathophysiology of hypoparathyroidism is complex and requires a multifaceted approach. Both
surgical and non-surgical forms pose diagnostic challenges. A clinical assessment to exclude syndromic
forms even in cases of apparent isolated disease, is always necessary in non-surgical, idiopathic hy-
poparathyroidism. The specific diagnostic testing is strongly driven by a proper clinical assessment to
exclude/confirm syndromic forms, even in cases of apparent isolated hypoparathyroidism. Transient
post-surgical hypoparathyroidism have to be ruled out, even in patients on long-term therapy with
calcium salts and active vitamin D. Since no highly specific and sensitive marker of parathyroid
autoimmunity exists, the diagnosis of autoimmune hypoparathyroidism is still a diagnosis of exclusion.
The proper definition of the etiopathogenesis of hypoparathyroidism has contributed a lot to better
understanding of parathyroid physiology and is fundamental to any therapeutic approach.
Summary
The terms hypoparathyroidism refers to a broad group of diseases of different etiology, all char-
acterized by the deficient levels of PTH leading to hypocalcemia and hyperphosphatemia, requiring
chronic replacement of calcium and active vitamin D. Besides post-surgical hypoparathyroidism, which
poses a diagnostic challenge as far as the recognition of transient forms are concerned, the develop-
ment of molecular endocrinology during the last two decades has greatly improved the diagnosis of
forms once names as idiopathic. The identification of genes responsible of syndromic and isolated
forms of non-surgical hypoparathyroidism has also improved the understanding of parathyroid
physiology. Epidemiological data on the prevalence, incidence and natural history of the disease are
still scarce and further cross-sectional and longitudinal studies are needed.
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indeed necessary, in order to plan the correct therapy and decrease the complications in the long term
(i.e. soft tissue calcifications, nephrolithiasis, nephrocalcinosis). Clinical assessment in non-surgical
forms is particularly important, since it can unveil associated, mainly asymptomatic non
parathyroid-related abnormalities pointing to syndromic hypoparathyroidism. Autoimmune hypo-
parathyroidism, which represents a substantial portion of the non-surgical forms, still does not have a
proper marker for diagnosis and, for this reason, is usually a diagnosis of exclusion.Practice points
 Hypoparathyroidism is complex disorder of mineral metabolism, whose physiopathology,
driven by the absence of proper PTH actions on a number of tissues and organs, include
many disturbances beyond the abnormal calcium homeostasis.
 With a mean prevalence of 25e30 cases in 100,000 inhabitants, hypoparathyroidism is
overall considered a rare disease, although the incidence of post-surgical hypoparathyroid-
ism can be higher in some settings, depending on the experience of the surgeon.
 Clinical screening of syndromic hypoparathyroidism is always recommended, even in cases
of apparently isolated hypoparathyroidism, both in children and in adults.
 Cytogenetic and genetic analyses have always to be undertaken in order to better diagnose
cases of idiopathic hypoparathyroidism and offer proper genetic counseling.
 It is mandatory to assess calcemia (and phosphatemia) within 1e4 days after neck surgery,
even in asymptomatic patients.
 Transient postsurgical hypoparathyroidism has to be ruled out even in supposedly perma-
nent/established hypoparathyroidism, in order to discontinue unnecessary long-term treat-
ment with calcium salts and active vitamin D, which can lead to long-term complications (soft
tissue calcifications, nephrolithiasis, nephrocalcinosis).
Research agenda
 Epidemiological data on the prevalence and incidence as well as on natural history of hy-
poparathyroidism are still needed in a number of settings.
 Shared protocols for structured clinical assessment in non-surgical forms are needed.
 Automated screening techniques of common genes in idiopathic hypoparathyroidism have
to be developed for differential diagnosis of non-surgical hypoparathyroidism.
 Better characterization of autoimmune hypoparathyroidism, with the finding of a specific and
sensitive marker has to be pursued.References
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